ESR1 and breast carcinoma: Furthermore, clinical investigations show that the higher expression of APOBEC3B is associated with a poorer survival rate for estrogen receptor-positive breast cancer patients, which includes brief periods of disease-free survival and, in particular, survival post-surgery [82].